Anzeige
Mehr »
Donnerstag, 28.08.2025 - Börsentäglich über 12.000 News
Neuer Uran-Boom: Die Warren Buffett-Chance im heißesten Wachstumsmarkt der kommenden Dekade!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A140ML | ISIN: JE00BYSS4X48 | Ticker-Symbol: 038
Tradegate
28.08.25 | 15:32
10,235 Euro
0,00 % 0,000
1-Jahres-Chart
NOVOCURE LIMITED Chart 1 Jahr
5-Tage-Chart
NOVOCURE LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
10,16010,25015:34
10,16010,25015:34

Aktuelle News zur NOVOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06Novocure Announces Upcoming Investor Events141Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief...
► Artikel lesen
NOVOCURE Aktie jetzt für 0€ handeln
13:03NovoCure Ltd - 8-K, Current Report2
MoSpanien nimmt Hirntumor-Therapie von Novocure in staatliches Gesundheitssystem auf5
MoNovocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain211Eligible patients can receive TTFields therapy through the Spanish National Health System Novocure (NASDAQ: NVCR) announced today that Spain's Ministry of Health has made Tumor Treating Fields...
► Artikel lesen
FrNVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer5
20.08.Novocure makes tumor-treating fields FDA PMA submission for treating pancreatic cancer3
20.08.Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer294WASHINGTON (dpa-AFX) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy...
► Artikel lesen
20.08.Novocure beantragt FDA-Zulassung für Therapie gegen Bauchspeicheldrüsenkrebs5
20.08.Novocure seeks FDA approval for pancreatic cancer treatment3
20.08.Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer213Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment...
► Artikel lesen
29.07.Why NovoCure Stock Is Cratering Today10
24.07.Novocure: Steady Ahead of Key Milestones21
24.07.Novocure Reports Second Quarter 2025 Financial Results616Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual...
► Artikel lesen
24.07.NovoCure Ltd - 10-Q, Quarterly Report2
24.07.NovoCure Ltd - 8-K, Current Report3
23.07.NovoCure Earnings Preview2
23.07.NovoCure Q2 2025 Earnings Preview4
08.07.NovoCure stock initiated with Buy rating at Ladenburg Thalmann4
08.07.Ladenburg Thalmann startet NovoCure-Aktie mit Kaufempfehlung9
03.07.NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data3
Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1